Navigation Links
Xencor Reports Second Quarter 2014 Financial Results
Date:7/31/2014

MONROVIA, Calif., July 31, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2014 and provided a review of recent business highlights.

"In the second quarter, we presented preclinical data at the American Thoracic Society 2014 International Conference (ATS) demonstrating three novel mechanisms of action of XmAb®7195, in development for the treatment of asthma, and we are now enrolling patients in a Phase 1a clinical trial. Our bispecific antibody program has yielded several potential lead candidates that target the immune system to specific cancer cells and that show potential to overcome the dosing and manufacturing hurdles that have plagued earlier generation bispecifics," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "The second half of this year is an exciting period for us as we approach preliminary data from both our XmAb®7195 and XmAb®5871 programs and selection of our lead bispecific for IND-enabling development."

Recent Business HighlightsXmAb7195

  • In May 2014, Xencor presented preclinical data on XmAb7195 at ATS demonstrating rapid IgE clearance by XmAb7195 compared to omalizumab. Results of the study found that after a single IV dose of XmAb7195 or omalizumab in chimpanzees, XmAb7195 reduced free IgE to at least 10-fold lower levels than omalizumab. In addition, XmAb7195 rapidly reduced free IgE levels to below quantifiable levels, until day 10. XmAb7195 depleted total IgE below quantifiable levels within one hour.
  • In May 2014, Xencor initiated a Phase 1a clinical trial of XmAb7195 in healthy subjects and all
    '/>"/>

  • SOURCE Xencor Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call
    2. Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
    3. Xencor, Inc. Announces Closing of Initial Public Offering
    4. Pharmacyclics Reports Second Quarter 2014 Results
    5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
    6. Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015
    7. HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013
    8. Endo Reports Second Quarter Financial Results
    9. Columbia Laboratories Reports Second Quarter 2014 Financial Results
    10. Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
    11. Hospira Reports Second-Quarter 2014 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
    (Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
    (Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
    Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
    ... Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively ... June 8 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... ) today announced results from a meta-analysis of cardiovascular (CV) ... with BYETTA(R) (exenatide) injection use compared to a pooled comparator ...
    ... Dose Optimization of Pre-Clinical Otelixizumab Surrogate , ... a biopharmaceutical company engaged in the discovery and ... presented results from a pre-clinical dose-optimization study conducted ... monoclonal antibody, otelixizumab, at the 69th Scientific Sessions ...
    Cached Medicine Technology:Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 2Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 3Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 4Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 5Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 6Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 3
    (Date:7/31/2015)... and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. ... , Glancing out of the window, he recalled that his equipment was set up ... Street tower, he jumped out of bed. , The photo speaks for itself. Chatfield ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair transplant ... they are the latest recipients of the Center of Clinical Excellence for ARTAS ... worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration is ...
    (Date:7/31/2015)... ... July 31, 2015 , ... ... contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. ... and post-acute care providers understand the benefits of using medication management technologies ...
    (Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... Practice, Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce ... in a mobile application format available on iPhones, iPads, and Android smartphones ...
    (Date:7/31/2015)... ... July 31, 2015 , ... “ Crack’em ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... make less mess while cooking. , Cooking can be a very messy experience, especially ...
    Breaking Medicine News(10 mins):Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Make Less Mess while Cooking with Crack’em 2
    ... Hair with MilkSAN CLEMENTE, Calif., May 4 Maintaining strong, ... including Latinas. So when a new product comes on ... hair, many ladies jump on the bandwagon. The beauty ... more on hair care products than other Americans, according to ...
    ... Quality, for Company,s Medical DevicesPITTSBURGH, May 4 ... ), manufacturers of noninvasive medical evaluation equipment used ... other disorders, said today that it has earned ... and services.Nystagmography is the recording and measurement of ...
    ... new safety regulations, , , MONDAY, May 4 (HealthDay News) -- ... a mother. , Last March, her 2-year-old son and ... dressed in the bathroom. , Stevenson heard a crash. She ... lying on top of her daughter. Her son, Michael, was ...
    ... team of researchers at The National Cancer Center Hospital in ... lung cancer resection surgery between 2000 and 2006. The study ... of Thoracic Oncology , the official journal of the International ... his team found that after classifying patients based on the ...
    ... Others Question the Continuing Use of Mercury , WASHINGTON, ... Consumers for Dental Choice and the Mercury Policy Project, ... DHR ) corporation to transition out of manufacturing mercury ... Hotel in Washington D.C. this Tuesday, May 5 at ...
    ... The medical director for the Los Angeles Jewish ... in the western United States, today shared the Home,s ... for and precautions to take as fear of swine ... are very similar to that of the flu bugs ...
    Cached Medicine News:Health News:Better Hair Days With Milk 2Health News:Better Hair Days With Milk 3Health News:Neuro Kinetics Earns ISO 13485 Certification 2Health News:More Kids Being Hurt by Falling Furniture 2Health News:More Kids Being Hurt by Falling Furniture 3Health News:Shareholders Challenge Danaher/Kerr to Phase Out Mercury Tooth Fillings 2Health News:Medical Director of Renowned Los Angeles Jewish Home Offers Advice to Seniors on Avoiding Swine Flu 2
    PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
    MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
    PxE thermal Cycler. 0.2ml, 96 well block holds 96 tubes or 1 x 96 well plate. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User f...
    ... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
    Medicine Products: